AbstractThe recent development of synthetic biology and system genomic open a new promising dimension for bioprocesses optimization. This induces an increasing complexity of applications in the biotechnology industry. Moreover, profitable bioprocesses design requires close collaboration between specialists as biologist, geneticist, or process engineer. As a consequence, the theoretic complexity of bioprocesses development steps is hardly increased. The implementations of efficient collaboration structures allowing to take profit from external opportunities are at the basis of strong competitive advantages for technological companies. Additionally, the uncertainty of technological innovations in live science is the second constraint to solve for allowing novelty emergence in biotechnology. This paper develops an organization and strategic framework which encompasses both industry and universities or public research centers. It highlights several keys aspects to cope efficiently with complexity and uncertainty. More precisely, this article suggests the interest to implement an efficient technological innovation framework considering three main dimensions: an appropriate human recourses management, a rational technological innovation strategy and an efficient collaborative network.
Frazzetto, G. (2003) White biotechnology. EMBO Rep. 4(9):835â€“837.
Becker, J., Wittmann, C. (2015) Advanced biotechnology: Metabolically engineered cells for the bio-based production of chemicals and fuels, materials, and health-care products. Angew Chem - Int Ed. 54(11):3328â€“3350.
Festel, G., Detzel, C., Maas, R. (2012) Industrial biotechnology - Markets and industry structure. J Commer Biotechnol. 18(1):11â€“21.
Gavrilescu, M., Chisti, Y. (2005) Biotechnology - A sustainable alternative for chemical industry. Biotechnol Adv. 23(7-8):471â€“99.
Woolston, BM., Edgar; S., Stephanopoulos, G. (2013) Metabolic engineering: Past and future. Annu Rev Chem Biomol Eng. 4:259â€“88.
Keasling, JD. (2008) Synthetic Biology for Synthetic Chemistry. ACS Chem Biol. 3(1):64â€“76.
Cosner, RR. (2010) Industrial Research Instituteâ€™s R&D Trends Forecast for 2010. Res-Technol Manag. 53(1):14â€“22.
Craig, V. Adams, MD., Myers, EW., Li, PW., Mural, RJ., Sutton, GG., et al. (2001) The sequence of the human genome. Science 291(5507):1304â€“1351.
Mehlman, SK., Uribe-Saucedo, S., Taylor, RP., Slowinski, G., Carreras, E., Arena, C. (2010) Better Practices for Managing Intellectual Assets in Collaborations. Res-Technol Manag. 53(1):55â€“66.
York, AS., Mc carthy, KA., Darnold, TC. (2009) Building biotechnology teams: Personality does matter. J Commer Biotechnol. 15(4):335â€“346.
McLaughlin, S. (2015) Characteristics of great bioscience leaders. J Commer Biotechnol. 21(1):65â€“68.
Behrens, W., Richert, A., Jeschke, S. (2015)
Development of a Questionnaire for the Screening of Communication Processes in Transdisciplinary Research Alliances. Int J Innov Manag Technol. 6(5):326â€“331.
Dodgson, M., Gann, DM., Salter, A. (2008) The Management of Technological Innovation: Strategy and Practice. OUP Oxford 604 p.
Ritu, B., Aifang, G., Namitha, S., (2014) Project selection in Innovation, technology, and knowledge management. Portland State University p. 29â€“51.
Gros, VL. (1992) Risk Management from a Technological Perspective. Geneva Pap Risk Insur - Issues Pract. 17(3):335â€“42.
Daim, TU., Pizarro, M., Talla, R. (2014) Planning and Roadmapping Technological Innovations: Cases and Tools. Springer Science & Business Media 281 p.
Wilson, GA., Perepelkin, J., Zhang, DD., Vachon, MA. (2014) Market Orientation, Alliance Orientation, and Business Performance in the Biotechnology Industry. J Commer Biotechnol. 20(2): 32-40.
Williamson, PJ. (1999) Strategy as options on the future. Sloan Manage Rev. 40(3):117â€“26.
Baltar, F. (2013) A Suitable â€œGPSâ€ for SMEâ€™s: the Strategic Planning and organizational Learning Nexus. J Knowl Manag Econ Inf Technol. (2).
Tzvi Raz, AJS. (2002) Risk Management, Project Success, and Technological Uncertainty. RampD Manag. 32(2):101â€“109.
David, L., Olson, JRB. (2014) Introduction to risk and uncertainty management in technological innovation. Technovation 34(8):395â€“368.
Samsonowa, BP. (2009) Defining KPI sets for industrial research organizations - a performance measurement approach. Int J Innovat Manage. 13(02):157â€“76.
Hirst, G., Mann, LA. (2004) Model of R&D leadership and team communication: The relationship with project performance. R Manag. 34(2):147â€“60.
Nieuwenhuizen, PJ., Lyon, D. (2011) Anticipating opportunities in industrial biotechnology: Sizing the market and growth scenarios. J Commer Biotechnol. 17(2):159â€“64.
Rao, SK. (2011) Pricing biologics: Issues, strategic priorities and a conceptual model. J Commer Biotechnol. 17(1):7â€“23.
Boni, AA. (2013) A Business Perspective on IP: Open Innovation vs. Open Source in Commercializing Biotechnology. J Commer Biotechnol. 19(2):55-59.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).